Patents for A61P 19 - Drugs for skeletal disorders (81,981)
07/2002
07/25/2002CA2434636A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use
07/25/2002CA2433879A1 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
07/25/2002CA2433313A1 Polypetides and nucleic acids encoding same
07/25/2002CA2430634A1 Proteins, polynucleotides encoding them and methods of using the same
07/25/2002CA2426775A1 Thienopyrimidine-based inhibitors of the src family
07/24/2002EP1225223A1 p21Cip1 REMEDIES FOR RHEUMATISM
07/24/2002EP1225183A2 Human G-protein coupled receptor
07/24/2002EP1224941A2 Antithrombin III used in diseases caused by angiogenesis
07/24/2002EP1224871A2 Compositions of Padina algae or their extracts, and their applications in foodstuffs or for the culture of molluscs or arthropodes
07/24/2002EP1224322A2 Gene sequence variations with utility in determining the treatment of disease
07/24/2002EP1224291A1 Multiple sclerosis-related superantigen
07/24/2002EP1224288A2 Processed human chemokines phc-1 and phc-2
07/24/2002EP1224213A2 Complex comprising an igfiie polypeptide-fragment and an igfbp2 polypeptide and its use in the treatment of osteoporosis
07/24/2002EP1224204A1 Non-aromatic estrogenic steroids with a hydrocarbon substituent in position 11
07/24/2002EP1224201A1 32 human secreted proteins
07/24/2002EP1224200A1 Tissue plasminogen activator-like protease
07/24/2002EP1224199A1 Transgenic mice containing trp gene disruptions
07/24/2002EP1224185A1 Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use
07/24/2002EP1224183A2 Heterocyclic sodium/proton exchange inhibitors and method
07/24/2002EP1224180A2 Substituted azoles
07/24/2002EP1224171A1 Beta disubstituted metalloprotease inhibitors
07/24/2002EP1224170A1 6-position substituted indoline, production and use thereof as a medicament
07/24/2002EP1224163A1 Use of carbonylamino derivatives against cns disorders
07/24/2002EP1223990A1 Formulations of hyaluronic acid for delivery of osteogenic proteins
07/24/2002EP1223988A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression
07/24/2002EP1223977A2 Modified plant viruses and methods of use thereof
07/24/2002EP1223974A2 Medicament in order to induce tolerance
07/24/2002EP1223966A2 Use of gdnf for treating corneal defects
07/24/2002EP1223965A2 Modulation of angiogenesis
07/24/2002EP1223961A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression
07/24/2002EP1223945A1 Compositions comprising oxophosphonate-based metalloproteinase inhibitors
07/24/2002EP1223943A2 Therapeutic use of an inhibitor or an antagonist of an abc protein in bone
07/24/2002EP1223940A2 Treatment of osteoporosis
07/24/2002EP1223932A1 Compounds and methods
07/24/2002EP1223918A1 Pharmaceutical compositions comprising a hmg coa reductase inhibitor
07/24/2002EP1223915A1 Dry powder compositions having improved dispersivity
07/24/2002EP1102743B1 Amide derivatives which are useful as cytokine inhibitors
07/24/2002EP1100767B1 Novel phenylethylamine derivatives, a method for the production thereof and their use as medicaments
07/24/2002CN1360596A Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith
07/24/2002CN1360590A Androgen glycosides and androgenic activity thereof
07/24/2002CN1360582A Quinazoline derivs.
07/24/2002CN1360581A Benzoylpyridazines
07/24/2002CN1360577A Hydroxamic acid derivs. as matrix metalloprotease inhibitors
07/24/2002CN1360572A Vitamin D3 Analogs
07/24/2002CN1360568A Diacylhydrazine derivs.
07/24/2002CN1359900A Metal protease inhibitor, preparing process thereof and pharmaceutical composition contg. same
07/24/2002CN1359706A Exterior-applied medicine for treating osteopathy
07/24/2002CN1359704A Process for preparing patch for treatment of cervicodynia
07/24/2002CN1359701A Aloe wine for treating injury
07/24/2002CN1359695A Bone setting-up pill
07/24/2002CN1087949C Medicine for treating ankylosing spondylitis and method for preparing same
07/23/2002US6423840 Forming n-acylamino compound
07/23/2002US6423713 Substituted pyrazoles as p38 kinase inhibitors
07/23/2002US6423712 2,4-Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
07/23/2002US6423710 Cyclic AMP-specific phosphodiesterase inhibitors
07/23/2002US6423700 17-halogenated 19-nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same
07/23/2002US6423507 Detecting enzyme inhibitors; obtain protease, incubate with modulator, monitor adjustment in protease activity
07/23/2002US6423347 Antiarthritic agents in liquid form
07/23/2002CA2365997A1 Novel polypeptide
07/23/2002CA2101556C Growth factor containing matrix for the treatment of cartilage lesions
07/18/2002WO2002055698A2 Transcriptional mediators of blood vessel development and endothelial differentiation
07/18/2002WO2002055547A2 Sfrp and peptide motifs that interact with sfrp and methods of their use
07/18/2002WO2002055541A2 Peptides having inhibiting activity on the production of nitric oxide
07/18/2002WO2002055532A2 Variant growth hormone molecules conjugated with macromolecular compounds
07/18/2002WO2002055531A1 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
07/18/2002WO2002055525A1 Retinoid agonists
07/18/2002WO2002055517A2 4-(hetero)aryl substituted indolinones
07/18/2002WO2002055507A1 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors
07/18/2002WO2002055502A1 Pyridine derivatives useful as cyclooxygenase inhibitor
07/18/2002WO2002055501A2 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
07/18/2002WO2002055499A1 Intermediates for the synthesis of pyridinoline and preparation thereof
07/18/2002WO2002055498A1 Pharmaceutically active piperidine derivatives
07/18/2002WO2002055491A2 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a)
07/18/2002WO2002055099A2 Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
07/18/2002WO2002055098A2 Latency associated peptide for providing latency to pharmaceutically active proteins
07/18/2002WO2002055087A1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
07/18/2002WO2002055077A1 Use of imidazolyl cyclic acetal derivatives in the manufacture of a medicament for the treatment of diseases mediated by the alk5 receptors
07/18/2002WO2002055075A2 Compounds and methods for regulating cell differentiation
07/18/2002WO2002055074A1 Preventives or remedies for arthritis
07/18/2002WO2002055073A1 Preventives for arthritis
07/18/2002WO2002055072A1 Regulation of lipids and/or bone density and compositions therefor
07/18/2002WO2002055067A2 Fumaric acid derivatives as nf-kappab inhibitors
07/18/2002WO2002055066A1 Fumaric acid derivatives as nf-kappa-b inhibitors
07/18/2002WO2002055064A2 Mucopolysaccharidosis therapies
07/18/2002WO2002055063A2 Fumaric acid amides
07/18/2002WO2002055016A2 INHIBITION OF NF-λB BY TRITERPENE COMPOSITIONS
07/18/2002WO2002054851A2 Inhibition of pathological angiogenesis in vivo
07/18/2002WO2002034280A3 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain
07/18/2002WO2002034202A3 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
07/18/2002WO2002029088A3 Highly expressible genes
07/18/2002WO2002022558A3 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
07/18/2002WO2002022557A3 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
07/18/2002WO2002016310A9 Selective androgen receptor modulators and methods of use thereof
07/18/2002WO2002013758A3 System for regulating in vivo the expression of a transgene by conditional inhibition
07/18/2002WO2002012249A3 Substituted pyrrole compounds and their use as spla2 inhibitors
07/18/2002WO2002011704A3 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases
07/18/2002WO2002006316A3 Alpha-msh related compounds and methods of use
07/18/2002WO2002006242A3 5-substituted 2-aryl-4-pyrimidinones
07/18/2002WO2002002633A3 Transporters and ion channels
07/18/2002WO2002002556A3 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS